Abzena

Abzena is expanding its team in the US with several pivotal leadership roles: -Sr. Director/Director of Bioconjugation in Bristol, PA -Principal/Sr. Scientist of Analytical Method Development in Bristol, PA -Principal/Sr. Scientist of Process Chemistry in Bristol, PA -Sr. Manager/Manager of Manufacturing in San Diego, CA -Sr. Manager/Manager of QC Microbiology in San Diego, CA   When you bring your talents to Abzena, you’ll be able to contribute to some of the most innovative development programs anywhere—collaborating with the brightest minds, sharing ideas, advancing knowledge and delivering real-world results. Come and make your mark with us!   Join us to advance biopharmaceutical innovation today: https://lnkd.in/eQmJJu_Z   #Biologics #AbzenaCareers #Biopharmaceuticals #CDMO #Bioconjugates #ADCs

Drug developers are often under pressure from stakeholders and investors to rapidly reach IND application and demonstrate a return on investment. But on the pathway to IND, cell line development (CLD) is a common bottleneck, sometimes taking up to a year to produce a stable cell line.   At Abzena, our AbZelect™ & AbZelectPRO™ Cell Line Development (CLD) platforms accelerate the production of high-yielding cell lines for antibodies and recombinant proteins. They enable us to rapidly progress biological drug programs toward the clinic by reducing timelines from DNA to research cell banks to 15 weeks.   Their exceptional productivity levels provide cost efficiencies that truly de-risk the drug development pathway by providing rapid production of material, technology transfer, process development, scale-up and manufacturing, all under a single organization.   Discover how our Cell Line Development can streamline your biologics development: https://lnkd.in/gwQVMgcu   #Biologics #CellLineDevelopment #CDMO #CRO #Bioconjugates

At Abzena, we empower our customers to reach their milestones through dedicated support and exceptional scientific expertise. Our extensive discovery through commercial capabilities cultivate long-term, productive partnerships while consistently delivering innovative solutions and high-quality data.   Susan Dexter, CTO of Sonnet BioTherapeutics, expressed: “Sonnet and Abzena have had a productive working relationship for years. This success has been based upon Abzena’s excellent science and, most importantly, the abilities of their project management team. I would also like to acknowledge Abzena’s scientific and technical staff, which has made many excellent suggestions and extra efforts contributing to the success of our projects. I hope to continue my interactions with Abzena’s project managers and scientists in the future for all of Sonnet projects.”   Discover how our team can help advance your complex biologic or ADC today: https://lnkd.in/ekuH3GV6 #CustomerSuccess #CRO #CDMO #Biologics #DrugDevelopment

Assessment of immunogenicity is crucial to predict potential adverse events and design safer biologics. We recently published a co-authored study with FDA on the use of the MHC Associated Peptide Proteomics (#MAPPs) assay to comprehensively evaluate the immunogenic potential of re-engineered variants of immunogenic FVIIa analog (Vatreptacog Alfa).    The study demonstrated how the MAPPs assay enables the identification of “relevant” T cell epitopes and and may contribute to the development of biologics with lower immunogenic potential.   Click here to access the publication: https://lnkd.in/ezn-mZQ4   #Immunogenicity #CDMO #CRO #DrugDevelopment 

Join us at the PBSS Workshop "Why All These New Modalities?" tomorrow at the Hyatt Regency La Jolla in San Diego. Explore the evolving landscape of new therapeutic modalities and the importance of diverse approaches for complex indications.    Abzena's Parviz A. Shamlou and Craig Magee, Ph.D. will be exhibiting at the event. So please make sure to swing by their table top to discuss your project specific needs and to learn how our cutting-edge capabilities can support your complex biologic or bioconjugate reach its next target inflection point faster!   Engage with industry leaders and discover the future of biopharmaceuticals:  https://lnkd.in/emsBXRSE   #Therapeutics #ADCCDMO #DrugDevelopment #CDMO #CRO

During Bone Cancer Awareness Month, we at Abzena are committed to advancing innovative therapeutic solutions to improve patient outcomes. Bone cancer is often considered to be rare and is frequently granted orphan drug designation, emphasizing the critical need for targeted treatments. Our work with antibody-drug conjugates (ADCs), including antibody radio-conjugates, exemplifies our dedication to creating therapies for orphan indications that enhance efficacy and minimize side effects, particularly for those with limited treatment options. Raising awareness and supporting research for bone cancer is vital. Together, we can make a difference in the lives of patients and their families in the rare disease community. #BoneCancerAwareness #OrphanDrugs #Oncology #ADCCDMO #RareDisease #PatientCare

At Abzena, we are focused on rapidly moving medicines forward by providing best-in-class, fully integrated CDMO + CRO services that streamline and de-risk the development pathway for complex #biologics and bioconjugates (#ADCs).    Our state-of-the-art facilities and expert scientific teams ensure high-quality, scalable, and efficient solutions for our customers that span from concept through commercialization.    By combining advanced technologies with decades of experience, we enable faster delivery of life-changing medicines to patients in need.   Discover how our comprehensive capabilities can help you achieve your next target inflection point faster- https://lnkd.in/gJiywnC2   #ADCCDMO #CDMO #CRO #DrugDevelopment #DrugSubstance

Our latest case study shows stochastic lysine-based #conjugation as a robust and scalable methodology to produce Antibody-drug Conjugates (#ADCs). The study details our advanced techniques and methodologies, demonstrating Abzena's commitment to delivering solutions in biopharmaceutical manufacturing. Access the full case study here: https://lnkd.in/eZdZevtu #ADCCDMO #DrugDevelopment #CDMO #CRO #ProcessDevelopment #ScalingProduction

Our latest blog features Eric Miller, Ian Glassford, PhD, MBA, and Louise Duffy discussing the important role that rapid analytics and platform strategies can play in accelerating novel #biotherapeutics toward the clinic.    Rapid analytics can enhance #manufacturability and reduce degradation, thus expediting toxicological material generation and ensuring a more robust formulation for use in the clinic.    At Abzena, our streamlined #analytical processes reduce risks, and accelerate timelines from candidate selection to clinical trials by leveraging standardized methods and advanced computational tools. We integrate data from all stages of development to provide actionable insights, support #IND applications, and speed up the transition from preclinical to Phase I and beyond    Access our blog to discover how Abzena’s analytical approach can expedite your biologic's development pathway: Rapid Analytics: https://lnkd.in/eamwSiuV #DrugDevelopment #CDMO #CRO #RapidAnalytics #PlatformStrategies 

Effective drug development often hinges on reliable and precise bioassays and analytics. In the early phases, ensuring the accuracy of these analyses is crucial for promising candidates to progress through the pipeline. At Abzena, we address these challenges with our comprehensive suite of early-phase bioassays and analytical services. Our state-of-the-art technologies and expert team provide robust solutions to accurately characterize and quantify biomolecules, ensuring high standards of precision and reliability. Our services cover a range of critical activities, including assay development, validation, and routine sample analysis. By integrating innovative methodologies, we enhance the data quality that underpins key decision-making in drug development. Explore how our early-phase bioassays and analytics can streamline your project from discovery to clinical development. Access our latest info sheet to learn more: https://lnkd.in/ee6FDKsc #Bioassays #Analytics #CDMO #CRO #DrugDevelopment #Biotechnology #Abzena